Seroprevalence of measles antibodies in women born between 1985 and 1999 in metropolitan city in India: a cross-sectional study Authors: Rujuta Hadaye, Pradnya D Chandanshive, Nishat Khan Published: 2024 ABSTRACT AbstractIntroductionThe Universal Immunisation Programme of India recommends first dose of measles vaccine in children at 9 months as the infant is protected by the maternal antibodies till then, and the vaccine provides optimal protection. However, during the recent outbreaks in 2023, in Mumbai, India, 31% of the measles cases reported till March end were infants below 9 months of age. The study was undertaken in view of increased vulnerability of infants below 9 months of age which might possibly indicate insufficient maternal antibodies against measles.Aim and objectivesTo estimate the seroprevalence of measles antibodies among women born between 1985 and 1999, most likely unvaccinated or vaccinated with a single dose of measles vaccine as per vaccination schedule prevalent then.MethodologyThis is a cross-sectional study conducted during November 2023 to January 2024 in the M/East municipal ward of the metropolitan city of Mumbai, Maharashtra, India. A total of 214 women were enrolled and interviewed at the nearest health centre. Their blood samples were analysed for IgG antibodies against measles using ELISA. Statistical analysis was performed to find the seroprevalence and its association with various factors using SPSS V.28.ResultsA total of 214 participants with a mean age of 30.9 years (SD= ±4.5) were included in the study. The mean measles IgG antibody titre among the participants was found to be 1.23 (SD= ±0.32) IU/mL, with as much as 37 (17.3%) women being seronegative for measles IgG. Thirty-four (15.9%) women had borderline (unequivocal) titre, and only 143 (66.8%) of the mothers had adequate antibodies to protect their infants.ConclusionAlmost one third of women exhibited insufficient antibodies to protect their babies. It was observed that those who have received measles vaccine in their childhood were more likely to have a positive measles antibody titre and immunity against the disease. WHAT IS ALREADY KNOWN ON THIS TOPIC Maternal antibodies against measles wane before 9 months, the age of eligibility of vaccination to infants, leaving the babies vulnerable to measles when measles vaccination coverage is suboptimal due to any reason. Maternal antibodies against measles wane before 9 months, the age of eligibility of vaccination to infants, leaving the babies vulnerable to measles when measles vaccination coverage is suboptimal due to any reason. WHAT THIS STUDY ADDS The study provides evidence to support the fact that a large section of women of reproductive age lacks measles antibodies and is under-protected. There is still a cohort of mothers which has received single or no doses of measles vaccine and is hence under-protected. The study highlights the importance of developing a strategy to cover this immunological gap to protect the mothers and babies. The study provides evidence to support the fact that a large section of women of reproductive age lacks measles antibodies and is under-protected. There is still a cohort of mothers which has received single or no doses of measles vaccine and is hence under-protected. The study highlights the importance of developing a strategy to cover this immunological gap to protect the mothers and babies. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY This study may provide basis for giving pre-pregnancy dose of measles vaccine. Multicentric study over large geographic areas may be planned to substantiate or refute the claim. The study also implies the necessity of robust routine immunisation programme as the vulnerability translates into outbreak situation when immunisation coverage rates fall as in pandemic situation. This study may provide basis for giving pre-pregnancy dose of measles vaccine. Multicentric study over large geographic areas may be planned to substantiate or refute the claim. The study also implies the necessity of robust routine immunisation programme as the vulnerability translates into outbreak situation when immunisation coverage rates fall as in pandemic situation. Introduction Measles, one of the most contagious but vaccine-preventable viral diseases affecting humans, causes an acute systemic infection with fever and respiratory compromise.1 It is caused by the measles virus, and in the susceptible population exposed to the virus has a transmission rate of 90%.2 Unvaccinated children, as well as pregnant women, are at a high risk of developing the disease and serious complications in case of an outbreak.3 The diagnosis is mainly clinical, and management is primarily supportive and helps prevent or treat complications, such as bacterial infections like otitis media, bronchopneumonia, laryngotracheobronchitis and diarrhoea.4 Children younger than 5 years of age and adults older than 20 years of age are more likely to suffer from complications. Nearly 1–3 of every 1000 children who become infected with measles die from respiratory and neurologic complications. Measles may also cause unvaccinated pregnant women to have a premature or low birthweight baby.5 Measles is entirely preventable by effective vaccination. An infant is protected against measles by maternal antibodies till the age of 9 months. The first dose of the measles vaccine is administered at 9 months of age as it provides the optimal response at that age.6 Individual countries introduced mass vaccination programmes against measles at the national level in the 1960s.7 India launched the Universal Immunisation Programme in 1985 with six antigens (BCG, oral polio (OPV), diphtheria, pertussis and tetanus (DPT) and measles), where measles vaccine was administered at 9 months of age.8 In 1999, MMR (Measles, Mumps, Rubella) was introduced as a single dose administered between 15 and 18 months of age.9 Since 2017, as per the national operational guidelines of the measles–rubella vaccination campaign and routine immunisation, the measles–rubella (MR) vaccine is administered in two doses, the first dose for children between 9 and 12 months of age and a second dose at 16–24 months of age.10 Hence, women born after 1999 are more likely to have received at least one or two doses of measles-containing vaccine in childhood. It is estimated that there were 9 million cases and 128 000 deaths due to measles in the year 2021 across the world with 22 countries witnessing outbreaks. The world is facing a large threat from measles due to the adverse effect of COVID-19 on immunisation and multiple outbreaks in the year 2022. Globally, there was an estimated 18% rise in measles cases and a 43% rise in measles deaths in the year 2022 than the previous year.11 Populations where around 40% of the children are susceptible to measles are prone to measles epidemics in almost all parts of the world.12 India’s strategy for measles and rubella elimination targets a 95% vaccination coverage for two doses of MR vaccine.13 A drop in vaccine coverage leaves children susceptible to the disease, as seen during the COVID-19 pandemic lockdown, where routine immunisation services suffered a great toll.14 The incidence of measles reduced by 62% during 2017–2021.15 However, numerous measles outbreaks were reported in India during 2022–2023 with the state of Maharashtra reporting the highest burden.16 The densely populated financial capital of the country, Mumbai, was the epicentre of the epidemic and was declared one of the 165 high-risk districts in the country for MR elimination activities.17 A strikingly high number of cases were reported from Mumbai—748 laboratory-confirmed cases and about 5300 epidemiologically linked cases with an incidence of 416.8 measles cases per million population in 2022 and 290 per million population in 2023.18 Such an enormous magnitude of cases in a city with a population density of roughly 73 000 per square mile is highly concerning, given the fact that Mumbai has one of the best public and private health infrastructure.19 This has also challenged the goal to achieve measles elimination in the year 2023. Alarmingly, Mumbai also reported 57 cases of infants below 9 months age in 2022 and 53 cases in 2023.18 It is believed that most infants are protected by maternal antibodies until 6–9 months of age.20 Infants below 9 months are not eligible for measles vaccination and therefore are vulnerable if maternal antibodies are insufficient to protect them.21 The occurrence of measles cases among infants below 9 months age might indicate insufficient maternal antibodies against measles, which is a grave issue as it increases the probability of mortality, vitamin A deficiency, corneal blindness among infants and children, in addition to subacute sclerosing panencephalitis years after an acute illness in children who suffered from measles within 2 years of age.22 Young infants are more likely to suffer complications including vitamin A deficiency, corneal blindness, pneumonia, diarrhoea and even mortality, and hence every effort must be ensured to protect them. Hence, a prepregnancy vaccine dose to mothers or early vaccination for infants may be required in settings with low measles vaccine coverage.23 The present study aims to ascertain the level of measles antibodies in those women born between 1985 and 1999 as they are likely to have received no dose or a single dose of the measles vaccine as per the vaccination schedule in this period, and assess their immunity against the infection as they are prospective mothers. This will help the policymakers to consider introduction of a prepregnancy dose to unvaccinated mothers or give an early measles dose in situations of compromised immunisation coverage. Material and methods Mumbai city is divided into 24 administrative wards, and each ward is considered as a district for implementing India’s national health programmes. The district under consideration- M/East ward, with a population of 807 720, is covered by the Integrated Child Development Services (ICDS) Scheme with an Anganwadi Centre (AWC) as a unit, per 1000 population, each managed by one anganwadi worker and a helper. Anganwadi is a mother and childcare centre started by the Government of India in 1975 under ICDS, with one ICDS block covering a population of 100 000.24 Minimum sample size of 210 was calculated based on proportion of seropositivity for measles IgG antibodies as 80%,25 and then applying a design effect of 1.5 to account for multistage sampling and anticipating non-response rate of 10%. As most Indian studies had estimated measles seroprevalence in children, the study by Wang et al25 from China in similar settings was chosen for reference as it included female adults.25 Four out of the six ICDS blocks (576 AWCs) under M/East ward were randomly selected, and to achieve the sample size of 200, 10 women were enrolled from 20 randomly selected AWCs. However, four more women in various centres, fulfilling inclusion criteria insisted in getting enrolled. They were included as this did not affect the study design adversely. The final sample size enrolled in the study was 214. Data collection for this cross-sectional study was completed over 2 months period from December 2023 to January 2024 in the M/East ward community which reported the earliest cases and deaths during October 2022 measles outbreaks. The study participants were women in the age group of 25 years–39 years, that is, those born between the years 1985 and 1999. Each participant’s blood sample collection (3 mL–5 mL) was performed at a nearest accessible health centre using venepuncture with all aseptic precautions by a qualified medical professional after recording the relevant sociodemographic information and related medical history. The blood samples were sent to the institutional Microbiology Laboratory which is an accredited laboratory. The samples were centrifuged and stored at −20°C and then tested for IgG antibodies against measles using Calbiotech Measles IgG ELISA kits (MS018G) for detection of IgG measles antibody in human serum or plasma. The cut-off for the antibody titre were considered as seronegative if <0.9 IU/mL, borderline positive from 0.9 to 1.1 IU/mL, and seropositive if>1.1 IU/mL as given in the kit insert. A semistructured interview schedule was used to collect participant data which were entered real time in Google sheets. The statistical analysis was done using percentages/proportions for categorical data, mean (SD) or median (IQR) for continuous data after applying tests of normality, and χ2 test/Fisher’s exact test for association. The data were analysed using Statistical Package for Social Sciences (SPSS) V.28. Ethics approval statement Ethics approval was granted by the Institutional Ethics Committee for Academic Research Projects (ECARP) (a Central Drugs Standard Control Organisation (CDSCO) registered committee) in June 2023 (Reference no. ECARP/2023/39). The study was conducted in accordance with the Declaration of Helsinki, ICH-Good Clinical Practice (1996) and Indian Council of Medical Research (ICMR) guidelines. Patient and public involvement statement Respondents of the study were not patients, but common women from the community. The community under study suffered the brunt of outbreaks and was supported by our urban health centre, where the children suffering from measles were isolated and cared for. The women had other family members including siblings of the ones suffering from measles and were reluctant to go to infectious diseases hospital. The seriousness of the young infants suffering from measles went beyond medical issues and had social repercussions as evident in the community. That prompted us to undertake research in intricacies of measles epidemiology and prioritise the immune status of prospective mothers. Results A total of 214 participants with a mean age of 30.9 years (SD= ±4.54) were enrolled in the study. Majority, that is, 70 of the participants belonged to the age group 24.1–28.1 years (32.7%), followed by 66 participants in the age group 28.2–32.1 years (30.8%), 46 between ages 32.2–36.1 years (21.5%) and 32 participants aged 36.2–40.1 years (15.0%). The mean measles IgG antibody titre among the participants was 1.23 (SD= ±0.32) IU/mL. The minimum antibody titre was 0.47 IU/mL and maximum was 2 IU/mL. An antibody titre <0.9 IU/mL was considered as seronegative, from 0.9 to 1.1 IU/mL as borderline positive and >1.1 IU/mL as seropositive. As many as 37 (17.3%) participants tested negative for measles antibodies, while 34 (15.9%) were borderline positive/intermediate. Only 143 (66.80%) women exhibited a positive antibody titre (table 1). Table 1Association between seropositivity and participant characteristics and historyAgeNegativeBorderlinePositiveχ2/ fisher’s exactP value 24.1–28.113 (35.1%)12 (35.3%)45 (31.5%)5.740.45 28.2–32.16 (16.2%)11 (32.4%)49 (34.3%) 32.2–36.111 (29.7%)7 (20.6%)28 (19.6%) 36.2–40.17 (18.9%)4 (11.8%)21 (14.7%) Total 37 (100.0%)34 (100.0%)143 (100.0%)BMI Underweight8 (21.6%)15 (44.1%)41 (28.7%)9.20.15 Normal3 (8.1%)2 (5.9%)21 (14.7%) Overweight20 (54.1%)16 (47.1%)61 (42.7%) Obese6 (16.2%)1 (2.9%)20 (14.0%)History of fever with rash/measles Yes6 (16.2%)8 (23.5%)28 (19.6%)5.450.56 No31 (83.7%)26 (76.4%)115 (80.4%)Recent history of measles Yes0 (0.0%)0 (0.0%)3 (2.1%)4.60.38 No37 (100.0%)34 (100.0%)140 (97.9%)Childhood immunisation card available at present Yes1 (2.7%)0 (0.0%)5 (3.5%)0.750.83 No36 (97.3%)34 (100.0%)138 (96.5%)H/O measles vaccine in childhood Don't know/cannot recall13 (35.1%)15 (44.1%)32 (22.4%)17.020.002* Yes5 (13.5%)0 (0.0%)34 (23.8%) No19 (51.4%)19 (55.9%)77 (53.8%)Measles vaccine received after 15 years of age Yes0 (0.0%)0 (0.0%)1 (0.7%)5.120.32 No37 (100.0%)34 (100.0%)142 (99.3%)Family history of measles in past 1 year Yes6 (16.2%)4 (11.8%14 (9.8%)1.450.49 No31 (83.8%)30 (88.2%)129 (90.2%)*P value significance: <0.05.BMIbody mass index Association between seropositivity and participant characteristics and history P value significance: <0.05. BMIbody mass index The average body mass index (BMI) of the women was 24 kg/m2 (SD= ±4.98) with a minimum BMI of 13.3 kg/m2 and maximum of 38.3 kg/m2. The BMI among the participants varied extremely as majority of the women were overweight with 97 (45.3%) having BMI of ≥27, followed by 64 (29.9%) who were underweight, and 27 (12.6%) women who were obese, while only 26 (12.1%) had a normal BMI. Out of the total, 41 individuals (19.20%) reported an unconfirmed history of measles (fever with rash) in childhood, out of which only 2 (0.9%) reported being hospitalised for the same. Three participants (1.40%) reported a history of measles within the last 6 months. Almost one-fifth of the participants, that is, 39 (18.20%) reported receiving the measles vaccine during their childhood, but as many as 208 (97.2%) did not have their childhood immunisation cards. Sixty (28.0%) participants could not recall receiving measles vaccine, while 115 (53.7%) confirmed not receiving measles vaccine. One participant (0.5%) confirmed receiving measles vaccine after the age of 15 years. As many as 24 participants (11.2%) had a recent family history of measles, of which more than half, that is, 13 (54.2%) women reported a recent history of measles affecting their sons, and 11 (45.8%) mentioned their daughters. The sisters of two (8.3%) and husband of one (4.2%) participant also reportedly suffered from measles during the outbreak period, with multiple family members reportedly being affected. Thirteen (35.1%) participants who were seronegative belonged to the age group 24.1–28.1 years. More than half, that is, 20 (54.1%) of the seronegative participants were overweight. These findings were not statistically significant (p>0.05) (table 1) A significant association was found between the participants’ history of missing measles vaccine in childhood and the absence of measles IgG antibodies. Out of the 115 participants who had not received measles vaccine in childhood, 19 (51.4%) were seronegative (Fisher’s Exact test=17.02, p=0.002). There was no significant association between seroprevalence of measles IgG antibody with any other variables (table 1). The age group of 28.2–32.1 years had the highest antibody titre with a median titre of 1.29 (IQR: 1.09–1.49) IU/mL as compared with the other age groups (figure 1). Antibody titre of participants across various age groups. Those participants who recalled receiving measles vaccine in their childhood showed the highest antibody titre with a median of 1.35 (IQR: 1.16–1.59) IU/mL as compared with those recalled not receiving the vaccine and those who did not recall their vaccine history(figure 2). Antibody titre of participants as per their childhood vaccination status. The antibody titre among the participants was normally distributed with less participants having antibody titre at extreme levels. Most of the participants’ antibody titre were found to lie in the borderline and positive range, giving a bell-shaped curve (figure 3). Antibody titre distribution among the participants (n=214). Discussion The purpose of this study was to estimate the seroprevalence and identify the immunity gap persisting in the reproductive age group women. Mumbai has faced a measles outbreak in 2022–2023 and these outbreaks are the most significant warning signals indicating gaps in immunisation coverage. Routine vaccination services are disrupted during acute humanitarian emergency situations resulting in increased vulnerability to communicable diseases, especially in children, women, and more importantly infants below the age of measles immunisation. This vulnerability is aggravated by overcrowding, poor sanitation and most importantly coexisting malnutrition.26 In this context, it is important to assess the seroprevalence of measles antibody in women of 1985–1999 birth cohort. The vaccination coverage data for the birth cohort of 1985–1999 are available only in NFHS data published in 1992–1993 and 1998–1999, which reported the measles vaccination coverage as 42% and 51% in NFHS 1 and 2, respectively, and vaccination coverage in Maharashtra or Mumbai is not available in public database for these periods. In a diverse country like India, the population data cannot be generalised. This signifies the importance of assessing seropositivity rather than doing survey on vaccination coverage data.27 28 As many as 40% women in this study were found to have inadequate antibodies, leaving them and their infants unprotected against measles. The seroprevalence for measles IgG antibodies was 66.8% among the study participants, which is lower compared other previous studies conducted in Sri Lanka, China, and USA.21 24 29 India is not the only country to experience recent measles outbreaks. In 2016–2020, China reported 344 measles outbreaks with 1886 cases. Sri Lanka faced an outbreak in 2013 while the USA has reported several measles outbreaks in the past decade. In view of these global outbreaks, appropriate public health measures are warranted which are tailored to the specific affected areas to reduce the proportion of susceptible population.3032 A similar seroprevalence was found in a study in Zambia, that is, 75% among women aged 18–40 years, before receiving MMR vaccine, which increased to 98% after MMR vaccination.33 Whereas, a much higher seroprevalence was seen in an Italian study among women born between 1972 and 1998, aged 19–44 years, reporting more than 95% seroprevalence, in which the higher seroprevalence among older age women is likely explained due to wild virus circulation between the years 1972 and 1977 in Italy.34 The total proportion of women with a negative antibody titre in this study was 17.30%. A study in Russia which compared measles antibody levels between healthy medical personnel of a maternity ward, and women in labour, reported that more than 20% were seronegative in each group. Such a high proportion of seronegative women in a hospital is also concerning due to a higher risk of nosocomial infections among the newborn babies in the maternity ward.35 In the current study setting, a significant number of seronegative women in reproductive age-group in the community not only puts the women at risk of various complications of measles, but also makes their infants and children vulnerable to the perils of the disease. Our study found a significant association between receiving measles vaccine in childhood and the seroprevalence of measles IgG antibodies, which corroborates with a Zambian study, where 92.4% females who were ever vaccinated for measles during ages 16–45 years tested seropositive for measles IgG antibodies.36 A Namibian study reported an overall seroprevalence of 87% among pregnant women in the age group of 15–44 years, which also emphasised the need for vaccination in women of reproductive age.37 However, we have our reservations on confirming any association of antibody levels with participants’ childhood vaccination history and measles history for a want of documentary evidence. Immunity against measles can be confirmed by serological evidence of positive titre of antibodies, whereas equivocal or borderline results are considered to be negative.38 Waaijenborg et al39 found low level of seropositivity among childbearing-age women in the Netherlands, suggestive of insufficient immunity among the latter.39 Measles vaccination for women of reproductive age can be pivotal to improve maternal antibody protection in infants as per the findings of the Zambian study by Malama et al.33 A systematic review and meta-analysis by Lochlainn et al40 and a cross-sectional study by Patel and Orenstein41 show evidence of diminishing IgG measles antibodies in infants as young as 4 months after birth, before they are eligible for MCV1 dose.40 41 The presence and level of antibodies in infants is also directly proportional to the antibody titre in the mother, but the antibody levels in infants fall after 3–4 months of age according to studies conducted in Greece and West Africa.42 43 Therefore, regardless of mothers’ immunisation status, infants are vulnerable to measles before receiving the first dose of measles vaccine, as the immunity conferred by wild-virus infection in mothers has been reported to surpass the immunity following vaccination which is short-lived.6 29 The high proportion of women with low BMI found in our study is additional risk factor for infection among these women and their children as their immunity is likely to be already compromised.44 Women have risk of infection even in their adulthood as per reports of measles among adults during the outbreak, and therefore their babies have a higher risk of contracting the infection from them.45 Only a fifth of the participants recalled receiving measles vaccine and/or having measles infection in their childhood. Although based on recall, the history of vaccination in such a small proportion of women is concerning with regards to their immunity against the disease. There is strong evidence for vaccine failure due to insufficient vaccine coverage for two doses of measles-containing vaccines.46 Reports of measles outbreaks in adults show evidence of serious complications such as pneumonitis, hepatic involvement, nephritis and miscarriage in the adult age groups, suggesting vulnerable adult population, especially with incomplete or lack of vaccination.47 Measles infection has also been reported to cause immunosuppression, emphasising the importance of measles vaccination to prevent the infection. Being a vaccine-preventable disease, infection and deaths due to measles as seen in multiple outbreaks is of grave concern.48 There have been reports of measles in infants under 9 months of age in countries such as Bangladesh, Nigeria and India.4952 It is of utmost importance to ensure robust immunisation services and maintain more than 95% coverage irrespective of emergencies or disasters of any kind, failing which, additional efforts will be required to protect women of questionable immunity and their newborn babies. This also poses a potential challenge to the goal of measles elimination by 2030. A policy prescription of considering either a prepregnancy vaccination or an early dose MCV1 in infants may be necessary in situation of impending outbreaks. The potential benefits of large-scale prepregnancy measles vaccination for women are significant in a region, where humanitarian emergencies and pandemics are likely to disrupt routine vaccination services. During humanitarian emergencies like COVID-19 pandemic, the focus is shifted towards the emergency response, leading to cancellation or postponement of vaccinations,14 and increased vulnerability to measles outbreak. Prepregnancy vaccination can help to bridge these immunity gaps and women and their newborns can be protected even when the routine services are interrupted. It cannot be overemphasised that babies face higher mortality risk and mothers face higher risk of infection, if the gap is not bridged. The prepregnancy vaccination may not be required all over the country, but could be implemented in high-risk zones/districts as suggested by the immunisation coverage rates. This may avoid cost of suffering and cost of intensified immunisation activities that follow outbreaks. The shift of routine first dose vaccination to an earlier age may reduce the susceptibility window between waning of maternal antibody and first vaccine dose in child.53 54 Prepregnancy vaccination is not a substitute for lower routine immunisation coverage and we strongly believe that no measure would be better than robust routine immunisation programme. However, the routine immunisations are not sustained in parts of huge countries and in various regions due to humanitarian emergencies like floods, landslides, civil wars and so on. At this moment, a large part of the world is facing such disruptions. Prepregnancy vaccination in this situation, can prevent the re-emergence of measles among women of childbearing age and their newborns, who might otherwise remain susceptible. Multicentric studies covering widespread geographical areas might be the way ahead to evaluate and support such a policy prescription. Strengths and limitations A quantitative estimation of IgG measles antibodies was performed using ELISA in an accredited laboratory. The study’s limitation is the recall-based history of measles vaccination and infection in women, especially due to lack of documentation. The ELISA kit serves merely as an aid to diagnosis and should be interpreted in relation to the patient’s history, physical findings and other diagnostic procedures, in addition, cross-reactivity is a known limitation of serological assays as mentioned in the insert of the kit. Conclusion Mothers and children are still underprotected when it comes to infectious diseases such as measles. It should be our goal to achieve a vaccine coverage more than 95% to prevent measles infection and outbreaks.